PAREXEL International

477 articles with PAREXEL International

• 

  BioSpace Movers and Shakers: Feb. 15

  2/15/2019

  Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.

• PAREXEL Appoints Former FDA Senior Executives to Global Regulatory Consulting Services

  2/12/2019

  The new additions join more than 60 former global regulators in the group and will be focused on helping companies understand and work within the current FDA and global regulatory climates to optimize drug development and mitigate risk of unnecessary delays.

• PAREXEL Receives Consecutive Recognitions from Forbes and FlexJobs for its Workplace Culture

  1/28/2019

  Company has once again been recognized for its diverse and flexible workplace by Forbes and FlexJobs.

• PAREXEL Introduces New Dedicated Division to Help Emerging Biotech Companies Reach their Goals Quickly and Cost-Effectively

  1/6/2019

  PAREXEL International Corporation today introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.

• PAREXEL Recognized with Awards for Innovation and Expertise in Real-World Evidence

  12/17/2018

  Recognitions include first-ever Scrip Award for Best Use of Real-World Evidence and “Best in Show” Fierce Innovation Award for partnership with Datavant, as FDA issues framework highlighting potential of RWE to industry

• PAREXEL Announces Change to Board of Directors

  12/13/2018

  Josef von Rickenbach will step down as Chairman of the Board of Directors effective December 31, 2018.

• PAREXEL Collaborates with Eli Lilly and Company to Develop China’s Clinical Research Workforce

  12/5/2018

  The program will bring high-value training opportunities to China’s clinical trial sites and investigators, enhancing the execution of local clinical trials and driving innovation in China’s biopharmaceutical industry.

• 

  Roivant Sciences Raises $200 Million, Bringing Its Valuation to $7 Billion

  11/13/2018

  Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.

• PAREXEL Announces Appointment of New Members to Its Board of Directors

  11/12/2018

  Today announced the appointment of new members to the Board of Directors following Pamplona Capital Management’s acquisition in September 2017.

• PAREXEL Navigates China’s Complex Drug Development and Market Landscape for Global Biopharmaceutical Companies with New China Advisory Service

  10/31/2018

  The offering leverages PAREXEL’s deep experience with and knowledge of the Chinese biopharmaceutical landscape to help companies navigate all aspects of the country’s drug development process.

• PAREXEL Announces Several New Patient-Centric Innovations to Address Drug Development Challenges

  10/9/2018

  Solutions Built on the Perceptive Cloud Platform Leverage Mobile and Wearable Technology

• PAREXEL Advances Patient-Centric Drug Development with Introduction of Its Patient Innovation Center

  9/11/2018

  The Center can help sponsors improve the drug development process by reducing the practical, financial and geographical barriers patients and caregivers often face, and optimize patient involvement and engagement.

• PAREXEL’s Xavier Flinois Named to 2018 PharmaVOICE 100

  8/1/2018

  PAREXEL International Corporation announced that Xavier Flinois, President of PAREXEL Informatics, has been named to PharmaVOICE magazine’s list of the 100 most inspiring people in the life sciences industry.

• 

  Biotech Manufacturing is Booming with Growth of Biologics and Gene Therapies

  7/5/2018

  Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.

• PAREXEL to Lead Discussions on Global Drug Development, Unveil New Industry Research at DIA Annual Meeting

  6/18/2018

  PAREXEL International Corporation announced today that several of its experts will discuss key issues facing the industry at the 54th Drug Information Association (DIA) Annual Meeting

• PAREXEL Receives Multiple Industry Recognitions for its Service to the Life Sciences Industry

  5/30/2018

  PAREXEL International Corporation announced that the Company has received recognition for its service and expertise from several notable industry organizations.

• Mark A. Goldberg, MD Joins Intensity Therapeutics, Inc. Board of Directors

  5/17/2018

  Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company's Board of Directors effective May 1, 2018.

• University of Texas System Initiative, Clinical Trials Xpress (CTX), Named as a PAREXEL Strategic Site Alliance Network Member

  4/26/2018

  Clinical Trials Xpress has been named by PAREXEL, the world's leading innovator of biopharmaceutical services, as a member of its Global Site Alliance Network.

• PAREXEL Announces Appointment of Peyton Howell as Chief Commercial and Strategy Officer

  4/25/2018

  Proven Healthcare Industry Leader will head PAREXEL’s Commercial Strategy

• PAREXEL’s Randomization and Trial Supply Management Service Recognized as Leader in Second Consecutive Industry Standard Research Benchmark Report

  4/17/2018

  PAREXEL’s ClinPhone® Randomization and Trial Supply Management cited as the most preferred and widely used Interactive Response Technology solution